A groundbreaking study published in Experimental & Molecular Medicine has unveiled a critical molecular mechanism that drives T cell activation within the psoriasis microenvironment, providing novel insights that could revolutionize therapeutic strategies for this chronic inflammatory skin disease. The research conducted by Zhu, Wang, Lin, and colleagues centers on the pivotal role of the transcription factor RUNX1 and its recruitment of the histone acetyltransferase GCN5 in keratinocytes, which consequently upregulates the expression of ICOSLG—a key ligand involved in the activation and modulation of T cells.
Psoriasis, characterized by abundant T cell infiltration and keratinocyte hyperproliferation, remains a therapeutic challenge due to its complex immunopathology. The current study pioneers a molecular pathway linking epigenetic regulation with immune activation that occurs within keratinocytes, the predominant cell type in the epidermis. RUNX1, previously recognized for its roles in hematopoiesis and immune cell differentiation, emerges here as a critical player in the skin’s immune milieu by influencing T cell dynamics via non-immune cells.
Using a combination of chromatin immunoprecipitation sequencing (ChIP-seq), RNA sequencing, and in vitro co-culture systems of keratinocytes and T cells, the researchers delineated a mechanism whereby RUNX1 binds to the promoter region of ICOSLG, recruiting GCN5 to induce histone acetylation marks. This epigenetic modification enhances ICOSLG transcription, which in turn increases co-stimulatory signaling to T cells. The ICOS-ICOSLG pathway is known for its importance in T cell activation and survival; thus, its upregulation within psoriatic keratinocytes provides a novel axis of pathological immune activation.
Remarkably, the intricate recruitment of GCN5 by RUNX1 highlights a sophisticated layer of transcriptional control grounded in chromatin structure remodeling. GCN5, as an acetyltransferase, modifies histone tails leading to a more relaxed chromatin state conducive to transcriptional activation. This epigenetic modification under keratinocyte control resolves longstanding questions regarding how non-immune cells within inflammatory niches actively participate in local immune regulation.
The study’s findings are robust across multiple experimental platforms, including knockdown models of RUNX1 and GCN5, which demonstrated significant decreases in ICOSLG expression and consequent attenuation of T cell activation markers such as CD69 and IFN-γ production. Furthermore, patient-derived psoriatic skin samples confirmed elevated RUNX1 and ICOSLG expression correlating with disease severity, establishing clinical relevance and potential biomarker utility.
This research breaks new ground by linking transcriptional regulation in keratinocytes directly to T cell-mediated psoriatic inflammation, effectively bridging innate epidermal function and adaptive immune dysregulation. The ability of keratinocytes to modulate T cell activation through an epigenetic mechanism adds a paradigm shift to the understanding of skin immunobiology and challenges the traditional immune-centered view of psoriasis pathogenesis.
Potential therapeutic implications are profound. Targeting the RUNX1-GCN5 interaction or the downstream epigenetic modifications offers a novel intervention point distinct from conventional immunosuppressive therapies currently in use. Such therapies could specifically disrupt pathogenic T cell activation within the skin without systemic immunosuppression, potentially reducing side effects and improving patient outcomes.
Beyond the immediate implications for psoriasis, this study raises intriguing possibilities in other T cell-mediated inflammatory diseases where tissue-resident cells might utilize similar epigenetic mechanisms to influence immune responses. The cross-talk between transcription factors and epigenetic modifiers in non-immune cells could represent a universal principle of immune regulation in inflammation.
From a technical perspective, this study employed cutting-edge next-generation sequencing and epigenomic profiling tools combined with sophisticated immunological assays to unravel the RUNX1-GCN5 axis. The integration of mechanistic molecular biology with patient sample validation emphasizes the translational nature of the research, ensuring that findings can be plausibly moved toward clinical application.
Moreover, the authors leveraged single-cell RNA sequencing datasets to verify that the upregulation of ICOSLG corresponds with distinct keratinocyte subpopulations, underscoring the cellular heterogeneity present in psoriatic lesions. This level of granularity provides new avenues for precision targeting of the pathogenic keratinocyte subsets.
The intricate relationship between RUNX1 and GCN5 also invites further exploration of other co-regulatory factors or post-translational modifications that might influence the specificity and timing of ICOSLG expression. Unraveling these layers of cellular control will be crucial to designing refined therapeutic agents that modulate epigenetic landscapes with high fidelity.
In addition to therapeutic development, these findings underscore the importance of re-examining the role of epithelial cells in immune diseases not merely as passive barriers but as active, epigenetically regulated participants in immune orchestration. This conceptual paradigm places keratinocytes at the forefront of future translational immunology investigations.
Overall, the study by Zhu et al. exemplifies how dissecting fundamental molecular mechanisms within tissue microenvironments can yield transformative insights into complex diseases like psoriasis. By uncovering the RUNX1-GCN5-ICOSLG axis, the authors have identified an innovative molecular target to disrupt the crosstalk that fuels chronic skin inflammation, with promising therapeutic prospects on the horizon.
The implications of this work extend beyond dermatology, signaling a shift toward epigenetic modulation strategies in immune-mediated disorders—a burgeoning field at the intersection of immunology, molecular biology, and therapeutic innovation. As we deepen our understanding of such pathways, personalized medicine approaches tailored to the unique epigenetic and transcriptional landscapes of patients will become increasingly attainable.
Future research stemming from this study will likely delve further into the complexity of epigenetic regulation within the skin’s microenvironment, explore pharmacologic agents that can selectively inhibit GCN5 or alter RUNX1 function, and validate these therapeutic strategies in clinical trials. The ultimate goal remains to alleviate the burden of psoriasis and potentially other autoimmune diseases through targeted, mechanism-driven treatments.
In conclusion, Zhu et al.’s discovery of RUNX1 recruitment of GCN5 in keratinocytes as a driver of ICOSLG expression and T cell activation in psoriasis provides an unprecedented glimpse into the epigenetic governance of immune activity in the skin. This revelation not only advances scientific understanding but also paves the way for next-generation therapies aimed at rebalancing immune responses in chronic inflammatory diseases.
Subject of Research: Molecular mechanisms of T cell activation in psoriasis microenvironment involving RUNX1, GCN5, and ICOSLG expression in keratinocytes.
Article Title: RUNX1 recruitment of GCN5 in keratinocytes upregulates ICOSLG and promotes T cell activation in the psoriasis microenvironment.
Article References:
Zhu, L., Wang, W., Lin, J. et al. RUNX1 recruitment of GCN5 in keratinocytes upregulates ICOSLG and promotes T cell activation in the psoriasis microenvironment. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01738-8
Image Credits: AI Generated
DOI: 04 June 2026
